From 982ee5df0ff4f8ecd05ce58f789d59cb34ecefa9 Mon Sep 17 00:00:00 2001 From: Teleo Agents Date: Wed, 18 Mar 2026 18:46:18 +0000 Subject: [PATCH 1/2] extract: 2026-01-13-aon-glp1-employer-cost-savings-cancer-reduction Pentagon-Agent: Epimetheus <968B2991-E2DF-4006-B962-F5B0A0CC8ACA> --- ...t cost impact inflationary through 2035.md | 6 ++++ ...-cardiovascular-and-metabolic-endpoints.md | 6 ++++ ...ients-undermining-chronic-use-economics.md | 6 ++++ ...just-clinical-factors-drive-persistence.md | 6 ++++ ...mployer-cost-savings-cancer-reduction.json | 32 +++++++++++++++++++ ...-employer-cost-savings-cancer-reduction.md | 17 +++++++++- 6 files changed, 72 insertions(+), 1 deletion(-) create mode 100644 inbox/queue/.extraction-debug/2026-01-13-aon-glp1-employer-cost-savings-cancer-reduction.json diff --git a/domains/health/GLP-1 receptor agonists are the largest therapeutic category launch in pharmaceutical history but their chronic use model makes the net cost impact inflationary through 2035.md b/domains/health/GLP-1 receptor agonists are the largest therapeutic category launch in pharmaceutical history but their chronic use model makes the net cost impact inflationary through 2035.md index 48849b28..dc77a05c 100644 --- a/domains/health/GLP-1 receptor agonists are the largest therapeutic category launch in pharmaceutical history but their chronic use model makes the net cost impact inflationary through 2035.md +++ b/domains/health/GLP-1 receptor agonists are the largest therapeutic category launch in pharmaceutical history but their chronic use model makes the net cost impact inflationary through 2035.md @@ -101,6 +101,12 @@ If GLP-1 + exercise produces durable weight maintenance (3.5 kg regain vs 8.7 kg Value in Health modeling study shows Medicare saves $715M over 10 years with comprehensive semaglutide access across all indications, challenging the universal inflationary framing. The distinction is payment structure: risk-bearing integrated payers can be net positive while fragmented systems remain inflationary. T2D savings ($892M) exceed obesity costs ($205M) when multi-indication benefits compound. + +### Additional Evidence (challenge) +*Source: [[2026-01-13-aon-glp1-employer-cost-savings-cancer-reduction]] | Added: 2026-03-18* + +Aon's temporal cost analysis shows medical costs rise 23% in year 1 but grow only 2% after 12 months (vs 6% for non-users), with diabetes patients showing 6-9 percentage point lower cost growth at 30 months. This suggests the 'inflationary through 2035' claim may only apply to short-term payers, while long-term risk-bearers see net savings. + --- Relevant Notes: diff --git a/domains/health/glp-1-multi-organ-protection-creates-compounding-value-across-kidney-cardiovascular-and-metabolic-endpoints.md b/domains/health/glp-1-multi-organ-protection-creates-compounding-value-across-kidney-cardiovascular-and-metabolic-endpoints.md index 5185921b..f889854e 100644 --- a/domains/health/glp-1-multi-organ-protection-creates-compounding-value-across-kidney-cardiovascular-and-metabolic-endpoints.md +++ b/domains/health/glp-1-multi-organ-protection-creates-compounding-value-across-kidney-cardiovascular-and-metabolic-endpoints.md @@ -60,6 +60,12 @@ Quantified lifetime savings per subject: $14,431 from avoided T2D, $2,074 from a Medicare modeling quantifies the compound value: 38,950 CV events avoided, 6,180 deaths prevented over 10 years. Per 100,000 subjects: 2,791 MIs, 3,000 revascularizations, 487 strokes, 115 CV deaths avoided. Savings per subject: $14,431 from avoided T2D, $2,074 from avoided CKD, $1,512 from avoided CV events. The multi-organ protection creates sufficient offset to produce net savings when a single payer captures all benefits. + +### Additional Evidence (extend) +*Source: [[2026-01-13-aon-glp1-employer-cost-savings-cancer-reduction]] | Added: 2026-03-18* + +Aon's 192K patient study found adherent GLP-1 users (80%+) had 47% fewer MACE hospitalizations for women and 26% for men, with the sex differential suggesting larger cardiovascular benefits for women than previously documented. + --- Relevant Notes: diff --git a/domains/health/glp-1-persistence-drops-to-15-percent-at-two-years-for-non-diabetic-obesity-patients-undermining-chronic-use-economics.md b/domains/health/glp-1-persistence-drops-to-15-percent-at-two-years-for-non-diabetic-obesity-patients-undermining-chronic-use-economics.md index c6673443..778dc751 100644 --- a/domains/health/glp-1-persistence-drops-to-15-percent-at-two-years-for-non-diabetic-obesity-patients-undermining-chronic-use-economics.md +++ b/domains/health/glp-1-persistence-drops-to-15-percent-at-two-years-for-non-diabetic-obesity-patients-undermining-chronic-use-economics.md @@ -83,6 +83,12 @@ WHO's conditional recommendation requiring behavioral therapy combination provid Weight regain data shows that even among patients who complete treatment, GLP-1 alone produces 8.7 kg regain (vs 7.6 kg placebo) while GLP-1 + exercise produces only 3.5 kg regain. This means low persistence may be economically rational for patients if the medication alone doesn't create lasting value—the 15% two-year persistence rate may reflect patients discovering that medication without lifestyle change produces temporary results. + +### Additional Evidence (extend) +*Source: [[2026-01-13-aon-glp1-employer-cost-savings-cancer-reduction]] | Added: 2026-03-18* + +Aon data shows the 80%+ adherent cohort captures dramatically stronger cost reductions (9 percentage points lower for diabetes, 7 points for weight loss), confirming that adherence is the binding variable for economic viability. The adherence-dependent savings pattern means low persistence rates eliminate cost-effectiveness even when clinical benefits exist. + --- Relevant Notes: diff --git a/domains/health/lower-income-patients-show-higher-glp-1-discontinuation-rates-suggesting-affordability-not-just-clinical-factors-drive-persistence.md b/domains/health/lower-income-patients-show-higher-glp-1-discontinuation-rates-suggesting-affordability-not-just-clinical-factors-drive-persistence.md index b9259e3a..9ebba0b0 100644 --- a/domains/health/lower-income-patients-show-higher-glp-1-discontinuation-rates-suggesting-affordability-not-just-clinical-factors-drive-persistence.md +++ b/domains/health/lower-income-patients-show-higher-glp-1-discontinuation-rates-suggesting-affordability-not-just-clinical-factors-drive-persistence.md @@ -43,6 +43,12 @@ The source does not provide granular income-stratified discontinuation rates, so The Trump Administration deal establishes a $50/month out-of-pocket maximum for Medicare beneficiaries, explicitly targeting affordability as a persistence barrier. The $245/month Medicare price (down from ~$1,350) combined with the OOP cap is designed to address the affordability-driven discontinuation pattern observed in lower-income populations. + +### Additional Evidence (confirm) +*Source: [[2026-01-13-aon-glp1-employer-cost-savings-cancer-reduction]] | Added: 2026-03-18* + +Aon's commercial claims data (employer-sponsored insurance) shows strong adherence effects, but the sample is biased toward higher-income employed populations. The fact that even in this relatively advantaged cohort, adherence is the key determinant of cost-effectiveness supports the claim that affordability barriers in lower-income populations would be even more binding. + --- Relevant Notes: diff --git a/inbox/queue/.extraction-debug/2026-01-13-aon-glp1-employer-cost-savings-cancer-reduction.json b/inbox/queue/.extraction-debug/2026-01-13-aon-glp1-employer-cost-savings-cancer-reduction.json new file mode 100644 index 00000000..e73be820 --- /dev/null +++ b/inbox/queue/.extraction-debug/2026-01-13-aon-glp1-employer-cost-savings-cancer-reduction.json @@ -0,0 +1,32 @@ +{ + "rejected_claims": [ + { + "filename": "glp-1-cost-effectiveness-requires-long-term-risk-bearing-because-savings-lag-drug-costs-by-12-18-months.md", + "issues": [ + "missing_attribution_extractor" + ] + }, + { + "filename": "glp-1-female-users-show-50-percent-ovarian-cancer-reduction-and-14-percent-breast-cancer-reduction.md", + "issues": [ + "missing_attribution_extractor" + ] + } + ], + "validation_stats": { + "total": 2, + "kept": 0, + "fixed": 2, + "rejected": 2, + "fixes_applied": [ + "glp-1-cost-effectiveness-requires-long-term-risk-bearing-because-savings-lag-drug-costs-by-12-18-months.md:set_created:2026-03-18", + "glp-1-female-users-show-50-percent-ovarian-cancer-reduction-and-14-percent-breast-cancer-reduction.md:set_created:2026-03-18" + ], + "rejections": [ + "glp-1-cost-effectiveness-requires-long-term-risk-bearing-because-savings-lag-drug-costs-by-12-18-months.md:missing_attribution_extractor", + "glp-1-female-users-show-50-percent-ovarian-cancer-reduction-and-14-percent-breast-cancer-reduction.md:missing_attribution_extractor" + ] + }, + "model": "anthropic/claude-sonnet-4.5", + "date": "2026-03-18" +} \ No newline at end of file diff --git a/inbox/queue/2026-01-13-aon-glp1-employer-cost-savings-cancer-reduction.md b/inbox/queue/2026-01-13-aon-glp1-employer-cost-savings-cancer-reduction.md index 0caf7034..2baecc91 100644 --- a/inbox/queue/2026-01-13-aon-glp1-employer-cost-savings-cancer-reduction.md +++ b/inbox/queue/2026-01-13-aon-glp1-employer-cost-savings-cancer-reduction.md @@ -7,9 +7,13 @@ date: 2026-01-13 domain: health secondary_domains: [internet-finance] format: report -status: unprocessed +status: enrichment priority: high tags: [glp-1, employer-costs, cancer-risk, cardiovascular, cost-offset, real-world-evidence] +processed_by: vida +processed_date: 2026-03-18 +enrichments_applied: ["glp-1-multi-organ-protection-creates-compounding-value-across-kidney-cardiovascular-and-metabolic-endpoints.md", "GLP-1 receptor agonists are the largest therapeutic category launch in pharmaceutical history but their chronic use model makes the net cost impact inflationary through 2035.md", "glp-1-persistence-drops-to-15-percent-at-two-years-for-non-diabetic-obesity-patients-undermining-chronic-use-economics.md", "lower-income-patients-show-higher-glp-1-discontinuation-rates-suggesting-affordability-not-just-clinical-factors-drive-persistence.md"] +extraction_model: "anthropic/claude-sonnet-4.5" --- ## Content @@ -49,3 +53,14 @@ WHY ARCHIVED: The temporal cost dynamics (costs up Y1, down Y2+) are the most im EXTRACTION HINT: Focus on the temporal cost curve and what it implies for different payment models. The cancer finding is separately important but preliminary. flagged_for_rio: ["GLP-1 cost dynamics have direct implications for health investment thesis — long-term risk-bearers capture savings that short-term payers miss"] + + +## Key Facts +- Aon analyzed 192,000+ GLP-1 users in U.S. commercial health claims data +- First 12 months on Wegovy/Zepbound: medical costs rise 23% vs 10% for non-users +- After 12 months: medical costs grow 2% vs 6% for non-users +- Diabetes indication at 30 months: medical cost growth 6 percentage points lower; 9 points lower with 80%+ adherence +- Weight loss indication at 18 months: cost growth 3 points lower; 7 points lower with consistent use +- Female GLP-1 users: ~50% lower ovarian cancer incidence, 14% lower breast cancer incidence +- Adherent users (80%+): 47% fewer MACE hospitalizations for women, 26% for men +- Study released January 13, 2026 -- 2.45.2 From 202d68a1599a8623e0fac30ae751d11157d26359 Mon Sep 17 00:00:00 2001 From: Teleo Agents Date: Wed, 18 Mar 2026 18:47:02 +0000 Subject: [PATCH 2/2] auto-fix: strip 4 broken wiki links Pipeline auto-fixer: removed [[ ]] brackets from links that don't resolve to existing claims in the knowledge base. --- ...model makes the net cost impact inflationary through 2035.md | 2 +- ...alue-across-kidney-cardiovascular-and-metabolic-endpoints.md | 2 +- ...abetic-obesity-patients-undermining-chronic-use-economics.md | 2 +- ...affordability-not-just-clinical-factors-drive-persistence.md | 2 +- 4 files changed, 4 insertions(+), 4 deletions(-) diff --git a/domains/health/GLP-1 receptor agonists are the largest therapeutic category launch in pharmaceutical history but their chronic use model makes the net cost impact inflationary through 2035.md b/domains/health/GLP-1 receptor agonists are the largest therapeutic category launch in pharmaceutical history but their chronic use model makes the net cost impact inflationary through 2035.md index dc77a05c..64f46f58 100644 --- a/domains/health/GLP-1 receptor agonists are the largest therapeutic category launch in pharmaceutical history but their chronic use model makes the net cost impact inflationary through 2035.md +++ b/domains/health/GLP-1 receptor agonists are the largest therapeutic category launch in pharmaceutical history but their chronic use model makes the net cost impact inflationary through 2035.md @@ -97,7 +97,7 @@ If GLP-1 + exercise produces durable weight maintenance (3.5 kg regain vs 8.7 kg ### Additional Evidence (challenge) -*Source: [[2025-06-01-value-in-health-comprehensive-semaglutide-medicare-economics]] | Added: 2026-03-18* +*Source: 2025-06-01-value-in-health-comprehensive-semaglutide-medicare-economics | Added: 2026-03-18* Value in Health modeling study shows Medicare saves $715M over 10 years with comprehensive semaglutide access across all indications, challenging the universal inflationary framing. The distinction is payment structure: risk-bearing integrated payers can be net positive while fragmented systems remain inflationary. T2D savings ($892M) exceed obesity costs ($205M) when multi-indication benefits compound. diff --git a/domains/health/glp-1-multi-organ-protection-creates-compounding-value-across-kidney-cardiovascular-and-metabolic-endpoints.md b/domains/health/glp-1-multi-organ-protection-creates-compounding-value-across-kidney-cardiovascular-and-metabolic-endpoints.md index f889854e..f02739da 100644 --- a/domains/health/glp-1-multi-organ-protection-creates-compounding-value-across-kidney-cardiovascular-and-metabolic-endpoints.md +++ b/domains/health/glp-1-multi-organ-protection-creates-compounding-value-across-kidney-cardiovascular-and-metabolic-endpoints.md @@ -56,7 +56,7 @@ Quantified lifetime savings per subject: $14,431 from avoided T2D, $2,074 from a ### Additional Evidence (confirm) -*Source: [[2025-06-01-value-in-health-comprehensive-semaglutide-medicare-economics]] | Added: 2026-03-18* +*Source: 2025-06-01-value-in-health-comprehensive-semaglutide-medicare-economics | Added: 2026-03-18* Medicare modeling quantifies the compound value: 38,950 CV events avoided, 6,180 deaths prevented over 10 years. Per 100,000 subjects: 2,791 MIs, 3,000 revascularizations, 487 strokes, 115 CV deaths avoided. Savings per subject: $14,431 from avoided T2D, $2,074 from avoided CKD, $1,512 from avoided CV events. The multi-organ protection creates sufficient offset to produce net savings when a single payer captures all benefits. diff --git a/domains/health/glp-1-persistence-drops-to-15-percent-at-two-years-for-non-diabetic-obesity-patients-undermining-chronic-use-economics.md b/domains/health/glp-1-persistence-drops-to-15-percent-at-two-years-for-non-diabetic-obesity-patients-undermining-chronic-use-economics.md index 778dc751..908bfeb4 100644 --- a/domains/health/glp-1-persistence-drops-to-15-percent-at-two-years-for-non-diabetic-obesity-patients-undermining-chronic-use-economics.md +++ b/domains/health/glp-1-persistence-drops-to-15-percent-at-two-years-for-non-diabetic-obesity-patients-undermining-chronic-use-economics.md @@ -79,7 +79,7 @@ WHO's conditional recommendation requiring behavioral therapy combination provid ### Additional Evidence (extend) -*Source: [[2026-03-01-glp1-lifestyle-modification-efficacy-combined-approach]] | Added: 2026-03-18* +*Source: 2026-03-01-glp1-lifestyle-modification-efficacy-combined-approach | Added: 2026-03-18* Weight regain data shows that even among patients who complete treatment, GLP-1 alone produces 8.7 kg regain (vs 7.6 kg placebo) while GLP-1 + exercise produces only 3.5 kg regain. This means low persistence may be economically rational for patients if the medication alone doesn't create lasting value—the 15% two-year persistence rate may reflect patients discovering that medication without lifestyle change produces temporary results. diff --git a/domains/health/lower-income-patients-show-higher-glp-1-discontinuation-rates-suggesting-affordability-not-just-clinical-factors-drive-persistence.md b/domains/health/lower-income-patients-show-higher-glp-1-discontinuation-rates-suggesting-affordability-not-just-clinical-factors-drive-persistence.md index 9ebba0b0..0c35f649 100644 --- a/domains/health/lower-income-patients-show-higher-glp-1-discontinuation-rates-suggesting-affordability-not-just-clinical-factors-drive-persistence.md +++ b/domains/health/lower-income-patients-show-higher-glp-1-discontinuation-rates-suggesting-affordability-not-just-clinical-factors-drive-persistence.md @@ -39,7 +39,7 @@ The source does not provide granular income-stratified discontinuation rates, so ### Additional Evidence (confirm) -*Source: [[2025-11-06-trump-novo-lilly-glp1-price-deals-medicare]] | Added: 2026-03-16* +*Source: 2025-11-06-trump-novo-lilly-glp1-price-deals-medicare | Added: 2026-03-16* The Trump Administration deal establishes a $50/month out-of-pocket maximum for Medicare beneficiaries, explicitly targeting affordability as a persistence barrier. The $245/month Medicare price (down from ~$1,350) combined with the OOP cap is designed to address the affordability-driven discontinuation pattern observed in lower-income populations. -- 2.45.2